JTWM
REGN icon

Jackson Thornton Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Jackson Thornton Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$606K Sell
972
-119
-11% -$81K 0.05% 120
2026
Q1 		$817K Buy
1,091
+101
+10% +$77.3K 0.07% 73
2025
Q4 		$769K Buy
990
+69
+7% +$46.9K 0.07% 75
2025
Q3 		$519K Buy
+921
New +$521K 0.05% 91

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Jackson Thornton Wealth Management's REGN Position: Q2 2026 in Review

Jackson Thornton Wealth Management reduced its Regeneron Pharmaceuticals (REGN) stake by 11% in Q2 2026, selling an estimated $81K and leaving 972 shares worth $606K. The position accounts for 0.05% of the portfolio, ranked #120.

Jackson Thornton Wealth Management first reported a position in REGN in Q3 2025 and has held it in 4 quarters since. The position peaked at $817K in Q1 2026. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Jackson Thornton Wealth Management held 972 shares of Regeneron Pharmaceuticals worth $606K as of Q2 2026.
  • Jackson Thornton Wealth Management sold 119 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $81K.
  • Regeneron Pharmaceuticals made up 0.05% of Jackson Thornton Wealth Management's portfolio in Q2 2026, its #120 holding.
  • Jackson Thornton Wealth Management first reported a position in Regeneron Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Jackson Thornton Wealth Management's Regeneron Pharmaceuticals position peaked at $817K in Q1 2026.
  • 1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Jackson Thornton Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.